Wegovy maker Novo shares slump as management grilled on pricing, M&A

Live updates

1. 2h ago

   Novo Nordisk Shares Slide as Strategy Fails to Quell Investor Doubts

   Novo Nordisk shares slumped as management faced tough questions regarding pricing pressures, mergers and acquisitions, and its post-Wegovy growth strategy. Investors expressed dissatisfaction during briefings outlining direct-to-consumer operations and plans targeting obesity markets. Chief executive officials detailed ambitions to introduce more than five blockbuster medications by 2030 and target a specific revenue goal by 2035. Meanwhile, competitor Viking Therapeutics reported strong trial results for an experimental obesity treatment, driving its stock up significantly.

   Why it matters

   The pharmaceutical giant faces mounting market pressure to prove its long-term viability beyond its current flagship weight-loss drug, Wegovy. Rival companies are aggressively advancing competing pipelines, leaving shareholders anxious about future revenue streams and drug pricing trends. The market reaction underscores intense scrutiny on how traditional drugmakers plan to adapt to shifting consumer and competitive dynamics.

   What is confirmed

   • Novo Nordisk aims to launch more than five blockbuster drugs by 2030.
   • Viking Therapeutics shares closed 35.7% higher at $40.85 following positive trial data for an experimental obesity treatment.
   • JP Morgan analyst Richard Vosser maintains a Neutral rating on Novo Nordisk stock with a target price of DKK 260.

   Still unconfirmed

   • Investors remain unconvinced by Novo Nordisk's plans to combat rival drugmaker Eli Lilly through new medications and direct-to-consumer initiatives.

   What to watch next

   • Execution of Novo Nordisk's strategy to hit its 2030 blockbuster and 2035 revenue targets
   • Further clinical developments and dosing data from competing obesity treatments like Viking Therapeutics
   Sources used for this update (10)

   1. CNBC — Novo shares slide as drugmaker lays out post-Wegovy growth strategy
   2. wsj.com — Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
   3. reuters.com — Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
   4. finance.yahoo.com — Novo Nordisk stock gets drilled on pipeline concerns — its CEO sees a main problem
   5. STAT — With new strategy, Novo outlines plans for obesity, direct-to-consumer work
   6. Fierce Pharma — Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
   7. BioSpace — Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
   8. www.devdiscourse.com — Reuters Health News Summary
   9. www.marketscreener.com — Amgen's autoimmune drug succeeds in late-stage trial
   10. www.marketscreener.com — Novo Nordisk A/S : JP Morgan reiterates its Neutral rating
   confidence 95%